BioSpace News Archive

Transparency Market Research has published a new report on the atherosclerosis drugs market.

The demand within the global market for acetabular prostheses has been rising on account of advancements in the field of bone replacement, prosthetics, and medical implants.

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced that members of management will participate in the following upcoming investor conferences:

Sanofi provides update on venglustat clinical program P ARIS – JUNE 1 , 20 21 – A pivotal Phase 2/3 study of venglustat in autosomal dominant polycystic kidney disease (ADPKD) did not meet futility criteria, and the company has halted the clinical program in ADPKD. The safety profile of venglustat remains consistent with previously reported results with more than 500 patients treated to date over a period of up to four years across all clinical programs. Biomarker data from th

GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ ® versus Natural History in Frontiers in Neurology Clinically meaningful difference between visual outcomes of LUMEVOQ ® -treated patients and untreated patients

Medivir AB announces that the company will present at the virtual meeting Redeye Growth Day on June 2, 2021.

Swedish Orphan Biovitrum AB will present data at the EHA virtual congress, 9-17 June 2021, highlighting the company’s advancement of treatments for rare haematological diseases.

Illumina, Inc. announced an agreement with the Belgian Genetic Centers to evaluate whole-genome sequencing for the diagnosis of patients with intellectual disabilities and/or developmental disorders in routine care.

Research by Maastricht University proves for the first time that insect protein is as beneficial as the ‘gold standard’ milk protein; both have the same performance on digestion, absorption and on the ability to stimulate muscle production.

Amgen and Kyowa Kirin Co., Ltd. announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin’s potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases.